REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Still a Buy?

REGENXBIO Inc. (NASDAQ:RGNX)’s share price gapped up before the market opened on Monday . The stock had previously closed at $8.65, but opened at $9.75. REGENXBIO shares last traded at $10.43, with a volume of 787,850 shares traded.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on RGNX and set a $30 price target (reduced from $32), signalling continued analyst conviction despite the cut; this provides some upside support for the stock. HC Wainwright Price Target Story
• Neutral Sentiment: Sector note — uniQure’s stock jumped after news about an FDA gene‑therapy official’s departure, a development that may influence broader gene‑therapy investor sentiment but is not directly about REGENXBIO. Sector moves can amplify volatility in RGNX. uniQure/FDA Story
• Negative Sentiment: Multiple law firms (Rosen, Pomerantz, Schall, Faruqi & Faruqi, Gross, Bronstein Gewirtz Grossman, Portnoy) have issued class‑action notices and are soliciting lead‑plaintiff applicants for the same February 2022–January 2026 class period with an April 14, 2026 deadline. This concentrated wave of litigation notices raises the likelihood of sustained legal expenses, management distraction, and potential settlement exposure — key reasons investors are selling or assigning a higher risk premium to the stock. Rosen Law Firm announcement: Rosen Notice Pomerantz alert: Pomerantz Notice Schall Law Firm notice: Schall Notice

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. The Goldman Sachs Group dropped their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Barclays initiated coverage on REGENXBIO in a report on Tuesday, January 27th. They set an “overweight” rating and a $37.00 target price on the stock. Morgan Stanley dropped their price target on REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Wall Street Zen downgraded REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Chardan Capital reduced their price objective on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

REGENXBIO Price Performance

The company has a market cap of $510.94 million, a price-to-earnings ratio of -2.63 and a beta of 1.08. The firm has a 50-day moving average price of $11.31 and a 200 day moving average price of $11.46.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.29). The firm had revenue of $30.34 million for the quarter, compared to analyst estimates of $45.48 million. REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%. On average, equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC increased its position in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares during the period. Assenagon Asset Management S.A. boosted its holdings in REGENXBIO by 64.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after purchasing an additional 454,977 shares during the period. Invenomic Capital Management LP bought a new stake in REGENXBIO in the 3rd quarter valued at about $4,120,000. Integral Health Asset Management LLC grew its position in shares of REGENXBIO by 57.1% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after purchasing an additional 400,000 shares in the last quarter. Finally, State Street Corp grew its position in shares of REGENXBIO by 15.2% during the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock worth $32,929,000 after purchasing an additional 301,858 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.